Australian Defence Force Selects GA-ASI’s MQ-9B for Project Air 7003
5.12.2019 04:28:00 EET | Business Wire | Press release
General Atomics Aeronautical Systems, Inc. (GA-ASI), the world’s leading manufacturer of Remotely Piloted Aircraft Systems (RPAS), has been advised that the Australian Government has selected GA-ASI’s MQ-9B SkyGuardian® variant to provide the Armed RPAS for the Australian Defence Force (ADF) under Project Air 7003. This follows the Government’s announcement in November 2018 that GA-ASI would provide Armed RPAS to the ADF. The ADF expects to take first delivery in the early 2020s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005989/en/
The Australian Government selected GA-ASI’s MQ-9B SkyGuardian® variant to provide the Armed RPAS for the Australian Defence Force under Project Air 7003. (Photo: Business Wire)
“We have worked closely with the ADF to determine the right RPAS to meet their needs,” said Linden Blue, CEO, GA-ASI. “MQ-9B will provide the all-weather, multi-mission support, and interoperability that the ADF requires. We look forward to working closely with our Australian industry partners to provide a highly capable RPAS to the ADF, while creating high-tech jobs in Australia.”
The ADF joins other top-tier military forces in choosing a GA-ASI RPAS because of its proven multi-role combat performance. MQ-9B is part of GA-ASI’s Predator® series of RPAS, which is the world’s most trusted and capable armed Medium-altitude, Long-endurance (MALE) RPAS, and hails from a family of aircraft that has flown more than six million flight hours.
The UK Royal Air Force (RAF) is acquiring the MQ-9B as part of its Protector RG Mk1 program and is scheduled for first delivery in the early 2020s. The Government of Belgium has approved Belgian Defense to negotiate for the acquisition of MQ-9B to meet the nation’s RPA requirements.
MQ-9B development is the result of a five-year, company funded program to deliver an unmanned aircraft system to meet the stringent airworthiness type-certification requirements of NATO and civil aviation authorities throughout the world. MQ-9B is provisioned for the GA-ASI-developed Detect and Avoid (DAA) system, which consists of air-to-air radar, Traffic alert and Collision Avoidance System (TCAS II), and Automatic Dependent Surveillance-Broadcast (ADS-B). The MQ-9B is built for all-weather performance with lightning protection, damage tolerance, and de-icing system.
GA-ASI announced its intention to offer a MALE RPAS to the ADF during AVALON 2017 with the launch of Team Reaper Australia, a robust group of Australian industry partners. The team currently consists of ten world-class Australian companies providing a range of innovative sensor, communication, manufacturing and life-cycle support capabilities including Cobham (lead industry partner), CAE, Raytheon, Flight Data Systems, TAE Aerospace, Quickstep, AirSpeed, Collins Aerospace, Ultra, and SentientVision.
Hi-resolution images of the MQ-9B SkyGuardian are available to qualified media outlets from the GA-ASI media contact list.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With nearly 6 million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.
Predator, SkyGuardian and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005989/en/
Contact information
Steven Henden
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8101
ASI-MediaRelations@ga-asi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom